Adverse effects of medical treatments appear to be underreported in peer-reviewed journal articles that describe clinical trial results, a new systematic review has found.

Vascular toxicity associated with cancer therapies is a leading cause of cardiovascular adverse events in patients with ...

Clinical trials, particularly in their pre-marketing phases, are inherently limited by sample size and duration, which can impede the detection of infrequent yet significant adverse events.

Methods: We conducted a Pubmed search of clinical trials evaluating the effect of CAR-T cell therapy in cancer patients with cardiovascular adverse events. For phase III trials, a quantitative ...

However, these patients also had higher rates of serious adverse events compared with those in clinical trials, especially cytokine release syndrome (CRS) and immune effector cell-associated ...

A significant issue is under enrollment of women in randomized trials, meaning the percentage of women enrolled isn’t in line ...

James Chalmers, MBChB, PhD, highlights the reassuring safety and tolerability profile of brensocatib in patients with non–cystic fibrosis bronchiectasis.

Thromboembolic adverse events are preventable. In a large randomized controlled trial (RCT) of primary thromboprophylaxis with rivaroxaban 10 mg once daily (v placebo) in ambulatory patients with ...

New observations of pericardial effusion adverse events in the clinical trial could signal potential safety issues that may pose regulatory challenges and hinder the drug's approval process. FAQ ...

Phase 1 clinical trials: These trials test the safety and dose range of a treatment in a small number of healthy volunteers (usually around 20 to 100). A phase 1 trial studies how a medication is ...